MediciNova Appoints Yutaka Kobayashi to Its Board of Directors

MediciNova Appoints Yutaka Kobayashi to Its Board of Directors

SAN DIEGO, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a
biopharmaceutical company that is publicly traded on the NASDAQ Global Market
(Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:
4875), today announced the appointment of Mr. Yutaka Kobayashi to its Board of

"We are extremely pleased and fortunate to add an individual with such strong
international and entrepreneurial experience to our Board of Directors," said
Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of
MediciNova, Inc. "We believe Mr. Kobayashi will be a great asset to the
company and its stockholders."

Mr. Kobayashi complements the MediciNova Board with more than 20 years of
experience in business. In addition, he was elected a member of Upper House in
Japan in 2001 and 2007. He graduated from Waseda University and was a Fellow
at Nitze School of Advanced International Studies at Johns Hopkins University.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet medical needs with a commercial focus on the U.S.
market. MediciNova's current strategy is to focus on its two prioritized
product candidates, MN-166 (ibudilast) for neurological disorders, and MN-221
for the treatment of acute exacerbations of asthma. MN-166 is being developed
in multiple indications, largely through investigator-sponsored trials and
outside funding. MediciNova is engaged in strategic partnering and consortium
funding discussions to support further development of both the MN-221 and
MN-166 programs. For more information on MediciNova, Inc., please visit

         Geoff O'Brien
         Vice President
         MediciNova, Inc.

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.